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Previewsimplicated proteins in future studies. An
understanding of the entire regulatory
network for pluripotency and reprogram-
ming from the viewpoint of protein
dynamics should facilitate the develop-
ment of new methods for more efficient
and safer reprogramming that will help
realize potential medical applications
for iPSCs.
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Two studies in this issue of Cell Stem Cell highlight context-dependent roles for MSCs in controlling tumor
growth. Lee et al. (2012) show that preactivated MSCs have antitumor effects upon adoptive transfer in vivo,
and Ren et al. (2012) show that tumor-resident MSCs can promote tumor growth by influencing macro-
phages.Inflammation is a key component of the
tumor microenvironment (Hanahan and
Weinberg, 2011; Mantovani et al., 2008).
The ecological niche of a tumor includes
inflammatory cells and mediators that
generally promote tumor progression
(Mantovani et al., 2008). Tumor-associ-
ated macrophages (TAMs) are a major
component of the leukocyte infiltrate
present in neoplastic tissues and play
a key role in cancer-related inflammation
through several different mechanisms,
including stimulation of angiogenesis,
promotion of growth, invasion andmetas-
tasis, and inhibition of antitumor immune
responses. Mesenchymal stromal/stem
cells (MSCs) are also present in tumor
stroma. In the tumor microenvironment,
stroma provides more than scaffolding
and MSCs are thought to act as precur-
sors for cancer-associated fibroblasts
(CAFs) (reviewed in Servais and Erez,2012). Together, MSCs and CAFs engage
in bidirectional interactions with cancer
cells and macrophages, which promote
tumor growth (Servais and Erez, 2012).
Two reports in this issue of Cell Stem
Cell shed new light and raise questions
on the role of MSCs in tumor progression
(Lee et al., 2012; Ren et al., 2012).
Lee et al. (2012) extend previous
studies on the antitumor activity of
MSCs expressing the proapoptotic mole-
cule TRAIL (e.g., Menon et al., 2009). They
report that MSCs that are preactivated by
inflammatory cytokines, TNF in particular,
or via activation of TLR3, express TRAIL
and have in vitro antitumor activity against
several human tumor cell lines by induc-
ing apoptosis. They also analyzed the
in vivo behavior of the TRAIL-expressing
MSCs in a xenograft model using a human
breast carcinoma cell line injected intra-
venously. They found that adoptive celltherapy with preactivated MSCs reduced
the size of tumor lesions in the lungs
and increased tumor cell death in situ.
In vitro, TNF-activated MSCs synergized
with doxorubicin, an anticancer drug, in
causing apoptotic cell death of breast
cancer cells. TNF-activated MSCs also
caused inhibition of cell cycle progression
in the breast carcinoma cells, a finding
presumably related to induction of the
cell cycle inhibitor Dickkopf3 (DKK3),
which is likely to contribute to the anti-
tumor activity in vivo (Figure 1).
In a separate paper, Ren et al. (2012)
dissect the tumor-promoting function of
MSCs using a primary mouse lymphoma
model, which was a major strength of
this study. To study tumor-resident
MSCs, they took advantage of sponta-
neous lymphomas developing in p53,
FasL, or MutL homolog-deficient mice.
The authors isolated the lymphomas,
Figure 1. MSC, Macrophages, and Cancer
Left: In a therapeutic setting based on adoptive cell transfer, TNF-activated, TRAIL-expressing MSCs can
express antitumor activity. Right: In carcinogenesis, MSCs engage in a bidirectional interaction with
TAMs, resulting in tumor promotion.
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Previewsseparated the associated MSCs, and
examined their influence on the growth
of unrelated tumors by coinjection of
MSCs with the T cell lymphoma line EL4
into syngeneic immunocompetent mice.
In contrast to the findings of Lee et al.,
Ren et al. found that MSCs isolated
from primary lymphomas have increased
tumor-growth-promoting activity. Inter-
estingly, this effect was indirect. MSCs
promoted tumors by increasing recruit-
ment of TAMs to the tumor site, inferred
because myeloid-specific ablation of
macrophages in transgenic mice pre-
vented MSC-mediated tumor growth.
Tumor-associated MSCs produced high
levels of inflammatory chemokines (e.g.,
CCL2), which recognize the chemokine
receptor CCR2, and the tumor promoting
effect of MSCs was abolished when lym-
phoma cells were transplanted together
with MSCs in CCR2 gene targeted mice
(Figure 1). Interestingly, the enhanced
tumor promoting activity of tumor-associ-
ated MSCs was mimicked by exposure of
normal bone-marrow-derived MSCs to
TNF. Evidence for the actual role of TNF
in the generation of tumor promoting
MSCs was obtained using TNF gene-
targeted mice, which contained fewer
MSCs in transplanted EL4 tumors. The
authors also related their findings to othertumor models and showed that TNF-
activated MSCs also promoted in-
creased macrophage recruitment and
faster growth of the B16 melanoma and
the 4T1 mammary carcinoma.
These results identify a ‘‘me´nage-a`-
trois’’ in a primary lymphoma and in trans-
planted solid tumors involving cancer
cells, MSCs, and macrophages. MSCs
contribute to cancer progression by
producing chemokines which, via CCR2,
recruit TAMs (Figure 1), a key element of
cancer-related inflammation (Mantovani
et al., 2008). Plasticity is a hallmark of cells
of the monocyte-macrophage lineage,
which undergo a spectrum of activation
states comprising classical (M1) and
alternative (M2) activation at either ex-
treme (Sica and Mantovani, 2012). TAMs
generally have an M2 or M2-like tumor
promoting phenotype, and macrophages
have also been reported to promote the
growth (Freytes et al., 2012) and motility
of MSCs. In turn, the present and previous
(Kim and Hematti, 2009) evidence
suggests that MSCs can induce an M2-
like phenotype in macrophages. CCL2
production by MSCs is likely to play
a role in driving the functional orientation
of TAM by MSCs, based on previous
findings (Zhang et al., 2010). Thus, macro-
phages and MSCs can engage in a bidi-Cell Stem Cell 11,rectional interaction resulting in tumor
promotion (Figure 1). It may therefore be
that tumor-associated MSCs contribute
not only to macrophage recruitment but
also to their protumor functions, possibly
by producing chemokines such as the
CCR2 ligand CCL2.
The results of the two current reports
may seem at odds with each other, point-
ing to inhibition (Ren et al., 2012) or stim-
ulation (Lee et al., 2012) of tumor growth
by TNF-activated MSCs. However, this
discrepancy may be more of an artifact
rather than a reflection of the physiolog-
ical reality of a tumor, and is in a way
reminiscent of the dual potential of TAM
(Mantovani et al., 2008). Lee et al. show
that demonstration of antitumor activity
requires relatively high numbers of
TRAIL-expressing MSCs in vitro or adop-
tive transfer in vivo. These conditions may
not reflect the in vivo reality that occurs
during carcinogenesis, as exhibited by
Ren et al., and may explain these
discrepant findings. While the physiolog-
ical relevance of TRAIL-expressing
MSCs for tumor formation is not clear, it
is important to remember that instead
these cells may be relevant in a thera-
peutic perspective. When considering
therapeutic application of the findings of
Lee et al., several outstanding questions
arise. It will be important to definewhether
and to what extent preactivated TRAIL-
expressing MSCs localize to solid tumors
situated in tissues other than lungs.
Furthermore, analyses should focus not
only on their distribution and survival,
but also their actual in vivo potential and
mode of action.
The two current reports (Lee et al.,
2012; Ren et al., 2012) alongwith previous
data highlight the potential importance
of the ‘‘me´nage-a`-trois’’ between tumor
cells, MSCs, and macrophages and raise
a number of questions. The actual spec-
trum of action, mechanisms of action,
and therapeutic potential of adoptive
transfer of TRAIL-MSCs remain unclear.
On the other hand, it will be important
to further explore the involvement of
MSCs in carcinogenesis using genetic
approaches. Tools need to be developed
to explore the presence of MSCs in
human tumors as well as their func-
tional and prognostic significance. The
challenge rests in translating a better
understanding of the complexity and
significance of this tripartite interactionDecember 7, 2012 ª2012 Elsevier Inc. 731
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Previewsinto novel diagnostic or therapeutic strat-
egies in the clinic.
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Recently in Cell, Jia et al. (2012) reported novel Utf1-controlled mechanisms of maintaining pluripotency and
self-renewal in embryonic stem cells (ESCs). Utf1 buffers bivalent gene expression by competitive binding
with polycomb repressive complex 2 and initiation of mRNA degradation.In 1998, Okuda et al. discovered a protein
expressed specifically in two pluripotent
cell lines: mouse embryonic carcinoma
cells (mECs) and mouse embryonic stem
cells (mESCs). Because of its restricted
expression pattern, the protein was
named Undifferentiated Embryonic Cell
Transcription Factor 1 (Utf1) (Okuda
et al., 1998). Utf1 is quickly downregu-
lated in mESCs during differentiation and
the protein is not expressed in somatic
cells. Van den Boom et al. (2007) later
identified Utf1 as a chromatin-associated
factor that is required for proper differen-
tiation of both mECs and mESCs. Now
Jia et al. (2012) have made a significant
advance in our understanding of not
only Utf1 itself, but also the regulatory
machinery controlling ESC pluripotency
and self-renewal, cellular processes in
which Utf1 plays integral roles.
Surprisingly, despite its name invoking
a surmised role as a transcription factor,
the activities of Utf1 in ESCs identified to
date do not appear to involve action as
a classical transcription factor. Jia et al.(2012) found instead that Utf1 contributes
to regulation of pluripotency by acting as
an epigenetic and translational factor. In
the former role, Utf1 fine-tunes the effects
of ESC-specific bivalent domains on gene
expression. Bivalent domains are epige-
netically regulated chromatin regions
that allow key developmental genes to
be poised in preparation for differentia-
tion, while concurrently maintaining low
levels of actual expression in the undiffer-
entiated state (Bernstein et al., 2006).
Bivalent domains are characterized by
a combination of large regions of re-
pressive H3 lysine 27 trimethylation
(H3K27me3) epigenetic marks, and
smaller regions of active H3 lysine 4
trimethylation (H3K4me3) epigenetic
marks. Jia et al. (2012) found that Utf1
contributes to regulation of pluripotency
by fine-tuning the effects of these ESC-
specific bivalent domains, in particular
via H3K27me3 and also by posttranscrip-
tional mRNA pruning.
Using ChIP-Seq tomap global genomic
DNA binding sites of Utf1 in mESCs, Jiaet al. (2012) reported approximately
75,000 chromatin regions bound by Utf1
including a large cohort of genes related
to organ/system development and cell
differentiation. RNA-Seq of Utf1 null
versus control mESCs identified almost
800 genes influenced by Utf1 levels by
at least 1.5-fold. Integrating the genomic
binding and RNA-Seq data sets revealed
that Utf1 directly bound most genes that
exhibited altered expression in ESCs
with Utf1 loss of function. Intriguingly,
the majority of these Utf1 target genes
were both bivalent and targets of poly-
comb repressive complex 2 (PRC2)
including its Suz12 subunit. They further
identified the mechanism of Utf1-medi-
ated gene upregulation, which involves
competing with PRC2 to bind an AG-rich
motif within CpG islands. It was already
known that PRC2 is required for estab-
lishing silenced and poised states of biva-
lent genes in ESCs (reviewed in Zhou
et al., 2011). Jia et al. (2012) propose
a model in which Utf1 prevents excessive
inhibition of bivalent genes by blocking
